Literature DB >> 21073608

Risk factors associated with gastric cancer in patients with a duodenal ulcer.

Soo-Jeong Cho1, Il Ju Choi, Chan Gyoo Kim, Myeong-Cherl Kook, Jong Yeul Lee, Byung Chang Kim, Kum Hei Ryu, Su Youn Nam, Young-Woo Kim.   

Abstract

BACKGROUND: Although gastric cancer (GC) and duodenal ulcer (DU) are both strongly associated with Helicobacter pylori infection, a DU is negatively associated with the risk of GC. The aim of the study is to evaluate histologic risk factors for GC among patients with a DU.
MATERIALS AND METHODS: A total of 541 consecutive patients with GC were prospectively evaluated for the presence of a DU. Control patients with only a DU (n = 89) were recruited from health screening population. Histologic grading was assessed using the updated Sydney system for six gastric biopsies from three regions. GC risk among patients with a DU was evaluated using logistic regression analysis.
RESULTS: Among patients with GC, 7.6% (41/541) had a concomitant DU or an ulcer scar. Corpus-predominant/pangastritis were more frequently found in concomitant GC patients with a DU (90%) than in patients with a DU alone (62%) (p = .001). In patients with a DU, moderate-severe chronic inflammation at the lesser and greater curvatures of corpus was associated with GC risk (OR, 3.70; 95% CI, 1.46-9.36, and OR, 7.72; 95% CI, 3.18-18.7, respectively). Additionally, moderate-severe intestinal metaplasia (IM) at the antrum and corpus lesser curvature was associated with GC risk (OR, 7.52; 95% CI, 3.06-18.5, and OR, 9.25, 95% CI, 2.39-35.8, respectively).
CONCLUSIONS: A DU is not rare in patients with GC in a high-risk region of GC. Patients with a DU with chronic corpus gastritis and IM have an increased risk of GC, thus those patients should be followed up for GC development.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 21073608     DOI: 10.1111/j.1523-5378.2010.00805.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  8 in total

Review 1.  Update on the Diagnosis and Management of Gastric Intestinal Metaplasia in the USA.

Authors:  Judy A Trieu; Mohammad Bilal; Hamzeh Saraireh; Andrew Y Wang
Journal:  Dig Dis Sci       Date:  2019-05       Impact factor: 3.199

2.  Follow-up of intestinal metaplasia in the stomach: When, how and why.

Authors:  Angelo Zullo; Cesare Hassan; Adriana Romiti; Michela Giusto; Carmine Guerriero; Roberto Lorenzetti; Salvatore Ma Campo; Silverio Tomao
Journal:  World J Gastrointest Oncol       Date:  2012-03-15

Review 3.  History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer.

Authors:  David Y Graham
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

4.  Gastric intestinal metaplasia is associated with gastric dysplasia but is inversely correlated with esophageal dysplasia.

Authors:  Justin M Gomez; James T Patrie; Wissam Bleibel; Jeanetta W Frye; Bryan G Sauer; Vanessa M Shami; Edward B Stelow; Christopher A Moskaluk; Andrew Y Wang
Journal:  World J Gastrointest Endosc       Date:  2017-02-16

Review 5.  β-Defensins in the Fight against Helicobacter pylori.

Authors:  Raffaela Pero; Lorena Coretti; Ersilia Nigro; Francesca Lembo; Sonia Laneri; Barbara Lombardo; Aurora Daniele; Olga Scudiero
Journal:  Molecules       Date:  2017-03-07       Impact factor: 4.411

6.  Risk factors for intestinal metaplasia in concomitant gastric and duodenal ulcer disease.

Authors:  Jun-Bo Hong; Liang Xia; Wei Zuo; An-Jiang Wang; Shan Xu; Hui-Fang Xiong; You-Xiang Chen; Xuan Zhu; Nong-Hua Lu
Journal:  Exp Ther Med       Date:  2014-01-28       Impact factor: 2.447

Review 7.  Helicobacter pylori Infection and Risk of Gastric Cancer in Korea: A Quantitative Systematic Review.

Authors:  Jong-Myon Bae; Eun Hee Kim
Journal:  J Prev Med Public Health       Date:  2016-07

8.  Potential role of aquaporin 3 in gastric intestinal metaplasia.

Authors:  Haijian Zhao; Xiaojun Yang; Yangchun Zhou; Weiming Zhang; Yao Wang; Jianfei Wen; Zhihong Zhang; Lizong Shen
Journal:  Oncotarget       Date:  2015-11-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.